Research Guides / Tirzepatide vs Retatrutide: Dual vs Triple Agonism Explained
9 min readTirzepatide added a second receptor to the GLP-1 formula and produced roughly 21% weight loss. Retatrutide adds a third and is reporting numbers approaching 29%.
The trajectory looks obvious: more receptors, more weight loss, another step up the ladder. The reality is more complicated -- not because the numbers are wrong, but because understanding what they mean requires knowing where in the development process they were generated, and what a third receptor actually costs.
Both drugs engage the GLP-1 receptor. Both engage the GIP receptor. Retatrutide adds the glucagon receptor.
Glucagon is the signal that tells your liver to release stored glucose. In isolation, that would be counterproductive for diabetes -- raising blood sugar is the opposite of what you want. But in the context of simultaneous GLP-1 and GIP activation, the net effect shifts. GLP-1's insulin-stimulating and glucagon-suppressing actions counterbalance glucagon's glucose-raising effect, while the glucagon component contributes two things the other receptors do not: increased energy expenditure and increased fat oxidation, particularly in the liver.
The liver-fat data illustrates this clearly. Tirzepatide, as a dual agonist, reduces liver fat. Retatrutide, adding glucagon, reduces it far more -- up to 82% relative change at 12 mg in the phase 2 body-composition substudy published in Nature Medicine. That is not a marginal improvement. It is a qualitatively different signal, and it suggests that the glucagon receptor may have specific utility for metabolic-associated steatohepatitis (MASH), a condition driven by liver fat accumulation.
But the same receptor also raises heart rate -- a consistent finding across glucagon-acting compounds -- and increases energy expenditure partly by increasing thermogenesis. That is metabolically useful but physiologically demanding. The question is not whether the glucagon receptor does something. It does. The question is whether the additional weight loss and liver-fat reduction justify the additional cardiovascular demand and a new side-effect profile.
| Tirzepatide | Retatrutide | |
|---|---|---|
| GLP-1 | Yes | Yes |
| GIP | Yes | Yes |
| Glucagon | No | Yes |
| Classification | Dual agonist | Triple agonist |
| Brand names | Mounjaro, Zepbound | None (investigational) |
| Research status | Approved | Phase 3 |
| Max weight loss reported | ~20.9% at 72 weeks (SURMOUNT-1) | ~28.3% at 80 weeks (TRIUMPH-1) |
The glucagon receptor is the reason retatrutide's liver-fat reductions are so striking -- up to 82% relative change at the 12 mg dose in the phase 2 body-composition substudy. That is not a marginal improvement. It is a qualitatively different signal. The question is whether the energy-expenditure benefit is worth the additional complexity and the new side-effect profile that comes with it.
Tirzepatide's data comes from the SURMOUNT program, a completed series of phase 3 trials that supported FDA approval. Retatrutide's data comes primarily from TRIUMPH, its phase 3 program, with earlier results from phase 2 studies published in peer-reviewed journals.
Both are randomized, double-blind, and placebo-controlled. The structures are comparable. But the stage of development is not, and that matters.
| Dimension | Tirzepatide (SURMOUNT) | Retatrutide (TRIUMPH / Phase 2) |
|---|---|---|
| Phase | 3 (completed, approved) | 3 (ongoing) / Phase 2 (published) |
| Peer-reviewed publications | Extensive (multiple NEJM, Lancet papers) | Growing (Lancet Diabetes & Endocrinology substudy, Nature Medicine) |
| Primary outcome met? | Yes, across multiple trials | Yes in phase 2; phase 3 results reported at conferences |
| Duration of longest trial | 72 weeks | 104 weeks (phase 3, conference report) |
| Regulatory submission | Complete (FDA approved) | Not yet submitted |
| Post-marketing safety data | Yes (years of real-world use) | None |
| Discontinuation due to adverse events | Dose-dependent, moderate | Higher at top doses; new signal: dysesthesia |
This is the section that matters most when comparing an approved drug to one still in trials.
Phase 2 trials establish whether a drug has a measurable effect and begin to characterize the dose-response relationship. They typically enroll a few hundred participants. They can generate striking results -- retatrutide's phase 2 data was genuinely impressive. But they have structural limitations that phase 3 is designed to address:
Sample size. Phase 2 is usually too small to detect uncommon side effects. A problem that affects 1 in 500 people may simply not appear. Phase 3 enrolls thousands, and uncommon events become visible.
Duration and follow-up. Phase 2 is often shorter. Long-term effects -- on bone density, on cardiac rhythm, on nutritional status -- take time to manifest.
Population breadth. Phase 2 often excludes complex patients. Phase 3 is where the real-world population -- with comorbidities, concurrent medications, and varied demographics -- enters. Effects that look clean in a selected group can change when the population broadens.
Retatrutide's phase 3 TRIUMPH data has been reported at medical conferences and in press releases as of mid-2026, showing weight loss of up to 28.3% at 80 weeks at the 12 mg dose, with the 104-week extension showing continued weight reduction up to 30.3% for participants with severe obesity. These are striking numbers. They are also preliminary -- the full peer-reviewed publications and the FDA's own review have not yet occurred.
The gap between a conference presentation and a peer-reviewed publication is not a formality. Peer review checks the analysis, questions the methodology, and can change how the results are interpreted. Conference data is useful. It is not final.
The most notable difference in retatrutide's side-effect profile is not gastrointestinal -- that was expected and is shared across the class. It is dysesthesia: abnormal skin sensations described as burning, tingling, or pins and needles. This appeared at higher rates in the retatrutide trials than in the GLP-1 or dual-agonist programs and led to treatment discontinuation for some participants.
Dysesthesia is not well-characterized in this context. Whether it is transient, dose-dependent, or persistent after discontinuation is still being studied. It may prove manageable. But it is a new signal that does not exist in the tirzepatide or semaglutide data at comparable rates, and it is the kind of finding that phase 3 is specifically designed to surface.
The other observation is the discontinuation rate. At retatrutide's highest dose (12 mg), a meaningful fraction of participants stopped the drug due to adverse events -- higher than the rate seen with tirzepatide at its highest dose in SURMOUNT. More weight loss, but harder to tolerate. That is the tradeoff.
There is a broader pattern worth noting. Across the GLP-1 class, higher efficacy has consistently correlated with higher discontinuation. Semaglutide 2.4 mg causes more GI side effects than 1 mg, and more people stop. Tirzepatide 15 mg causes more than 10 mg, and more people stop. Retatrutide 12 mg continues that trend. The relationship between dose, efficacy, and tolerability appears to be a class-wide curve, and retatrutide is simply further along it.
Tirzepatide is an approved drug with years of post-marketing experience. Its efficacy and safety profile are well-characterized. Retatrutide is a more powerful tool -- the triple-agonist data makes that clear -- but it is earlier in the process, and the safety profile is less established.
The counterargument for retatrutide is straightforward: the weight-loss numbers are substantially larger, and for patients with severe obesity -- particularly those with comorbidities like MASH, obstructive sleep apnea, or osteoarthritis -- the additional reduction may meaningfully change outcomes that a 21% loss from tirzepatide does not fully address. The TRIUMPH data showing 73% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity are not marginal improvements. For patients living with those conditions, the clinical relevance is clear.
Whether the additional weight loss justifies the additional uncertainty is a clinical question, not a scientific one. It depends on the individual patient's risk factors, the available alternatives, and how much is known at the time of the decision. That calculus will look different once retatrutide has completed its regulatory review than it does now.
This article is educational and not medical advice. It describes published clinical trial results and does not recommend any compound, dose, or protocol. Tirzepatide is a prescription medication; retatrutide is an investigational drug not yet approved by the FDA. Decisions about any therapy belong with a qualified clinician who knows your history.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.